Biomarker Hsp90 for predicting effect of a c-Met inhibitor

A method of selecting a subject for application of a c-Met inhibitor, the method comprising:

• measuring Hsp90 alpha protein level and/or Hsp90 alpha gene expression level,
• detecting a mutation of Hsp90 alpha and/or an Hsp90 alpha coding gene;
• or a combination thereof,
• in a biological sample from a patient with lung cancer,
• and
• selecting the patient for application of the c-Met inhibitor, when
• the Hsp90 alpha protein level or the Hsp90 alpha gene expression level in the biological sample from the patient is lower than that of a reference sample in which the c-Met inhibitor has no effect, and/or the mutation of Hsp90 alpha or the Hsp90 alpha coding gene is identified in the biological sample,
• wherein the mutation of Hsp90 alpha is C598A, I128T, or a combination thereof, of human Hsp90 alpha, and the Hsp90 alpha coding gene is a gene encoding a human Hsp90 alpha comprising the mutation of C598A, I128T, or a combination thereof,
• the method further comprising administering the c-Met inhibitor to the patient if
• (a) the Hsp90 alpha protein level or the Hsp90 alpha gene expression level in the biological sample from the patient is lower than that of a reference sample in which the c-Met inhibitor has no effect, and/or
• (b) the mutation of Hsp90 alpha or the Hsp90 alpha coding gene is identified in the biological sample.